Jazz Veno-Occlusive Disease Drug Defitelio OK'd
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals PLC won the FDA's approval on March 30 for the company's anticoagulant Defitelio (defibrotide) as a treatment for adults and children with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) – the first medicine available in the US for that indication.